New Data Shows AbbVie’s VENCLYXTO®/VENCLEXTA® Fixed Duration Combination Demonstrates Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients after Three Years off Treatment
The Pharma Data
JUNE 18, 2021
Advise nursing women to discontinue breastfeeding during treatment. 2014 Review of Cancer Medicines on the WHO List of Essential Medicines. 7 VENCLEXTA (venetoclax) [Package Insert]. For patients with severe (Child-Pugh C) hepatic impairment, a dose reduction of at least 50% throughout treatment is recommended. AbbVie Inc.
Let's personalize your content